Safety and efficacy of convalescent plasma for COVID-19: the preliminary results of a clinical trial
Background. The lack of effective etiotropic therapy for COVID-19 has prompted researchers around the globe to seekr various methods of SARS-CoV-2 elimination, including the use of convalescent plasma. Aim. The aim of this work was to study the safety and efficacy of the convalescence plasma treatment of severe COVID-19 using the plasma containing specific antibodies to the receptor binding domain (RBD) of SARS-CoV-2 S protein in a titer of at least 1:1000. Methods. A single-center, randomized, prospective clinical study was performed at the FRCC FMBA of Russia with the participation of 86 patients who were stratified in two groups. The first group included 20 critically ill patients who were on mechanical ventilation the second group included 66 patients with moderate to severe COVID-19 and with spontaneous respiration. The patients in the second group were randomized into two cohorts in a ratio of 2:1. In the first cohort (46 patients), pathogen-reduced convalescent plasma was transfused (twice, 320 ml each), in the second cohort (20 patients) a similar amount of non-immune freshly frozen plasma was transfused to the patients. Results. The use of plasma of convalescents in patients with severe COVID-19 being on mechanical ventilation does not affect the disease outcome in these patients. The mortality rate in this group was 60%, which corresponds to the average mortality of COVID patients on mechanical ventilation in our hospital. In the second group, clinical improvement was detected in 75% and 51%, for convalescent and non-immune plasma, respectively. Of the 46 people who received convalescent plasma, three patients (6.5%) were transferred to mechanical ventilation, two of them died. In the group receiving non-immune plasma, the need for mechanical ventilation also arose in three patients (15%), of which two died. The hospital mortality in the group of convalescent plasma was 4.3%, which is significantly lower than the average COVID-19 hospital mortality at our Center (6.73%) and more than two times lower than the hospital mortality in the control group (n=150), matched by age and by the disease severity. Conclusions. Thus, we demonstrated a relative safety of convalescent plasma transfusion and the effectiveness of such therapy for COVID-19 at least in terms of the survival of hospitalized patients with severe respiratory failure without mechanical ventilation. In the absence of bioengineered neutralizing antibodies and effective etiotropic therapy, the use of hyperimmune convalescent plasma is the simplest and most effective method of specific etiopathogenetic therapy of severe forms of COVID-19..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Клиническая практика - 11(2020), 2, Seite 38-50 |
| Sprache: |
Russisch |
|---|
| Beteiligte Personen: |
Vladimir P. Baklaushev [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Antibodies to rbd s-protein |
|---|
| doi: |
10.17816/clinpract35168 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ050131435 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ050131435 | ||
| 003 | DE-627 | ||
| 005 | 20230502063616.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230227s2020 xx |||||o 00| ||rus c | ||
| 024 | 7 | |a 10.17816/clinpract35168 |2 doi | |
| 035 | |a (DE-627)DOAJ050131435 | ||
| 035 | |a (DE-599)DOAJ8ff9fe1e117f46e6a130b2e1ed1f0f40 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a rus | ||
| 100 | 0 | |a Vladimir P. Baklaushev |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Safety and efficacy of convalescent plasma for COVID-19: the preliminary results of a clinical trial |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Background. The lack of effective etiotropic therapy for COVID-19 has prompted researchers around the globe to seekr various methods of SARS-CoV-2 elimination, including the use of convalescent plasma. Aim. The aim of this work was to study the safety and efficacy of the convalescence plasma treatment of severe COVID-19 using the plasma containing specific antibodies to the receptor binding domain (RBD) of SARS-CoV-2 S protein in a titer of at least 1:1000. Methods. A single-center, randomized, prospective clinical study was performed at the FRCC FMBA of Russia with the participation of 86 patients who were stratified in two groups. The first group included 20 critically ill patients who were on mechanical ventilation the second group included 66 patients with moderate to severe COVID-19 and with spontaneous respiration. The patients in the second group were randomized into two cohorts in a ratio of 2:1. In the first cohort (46 patients), pathogen-reduced convalescent plasma was transfused (twice, 320 ml each), in the second cohort (20 patients) a similar amount of non-immune freshly frozen plasma was transfused to the patients. Results. The use of plasma of convalescents in patients with severe COVID-19 being on mechanical ventilation does not affect the disease outcome in these patients. The mortality rate in this group was 60%, which corresponds to the average mortality of COVID patients on mechanical ventilation in our hospital. In the second group, clinical improvement was detected in 75% and 51%, for convalescent and non-immune plasma, respectively. Of the 46 people who received convalescent plasma, three patients (6.5%) were transferred to mechanical ventilation, two of them died. In the group receiving non-immune plasma, the need for mechanical ventilation also arose in three patients (15%), of which two died. The hospital mortality in the group of convalescent plasma was 4.3%, which is significantly lower than the average COVID-19 hospital mortality at our Center (6.73%) and more than two times lower than the hospital mortality in the control group (n=150), matched by age and by the disease severity. Conclusions. Thus, we demonstrated a relative safety of convalescent plasma transfusion and the effectiveness of such therapy for COVID-19 at least in terms of the survival of hospitalized patients with severe respiratory failure without mechanical ventilation. In the absence of bioengineered neutralizing antibodies and effective etiotropic therapy, the use of hyperimmune convalescent plasma is the simplest and most effective method of specific etiopathogenetic therapy of severe forms of COVID-19. | ||
| 650 | 4 | |a sars-cov-2 | |
| 650 | 4 | |a covid-19 | |
| 650 | 4 | |a plasma of convalescents | |
| 650 | 4 | |a antibodies to rbd s-protein | |
| 650 | 4 | |a ards | |
| 650 | 4 | |a mechanical ventilation | |
| 653 | 0 | |a Medicine | |
| 653 | 0 | |a R | |
| 700 | 0 | |a Alexander V. Averyanov |e verfasserin |4 aut | |
| 700 | 0 | |a Anna G. Sotnikova |e verfasserin |4 aut | |
| 700 | 0 | |a Anastasia S. Perkina |e verfasserin |4 aut | |
| 700 | 0 | |a Alexander V. Ivanov |e verfasserin |4 aut | |
| 700 | 0 | |a Gaukhar M. Yusubalieva |e verfasserin |4 aut | |
| 700 | 0 | |a Oksana N. Novikova |e verfasserin |4 aut | |
| 700 | 0 | |a Valentina E. Shikina |e verfasserin |4 aut | |
| 700 | 0 | |a Nikolay V. Dupik |e verfasserin |4 aut | |
| 700 | 0 | |a Anna G. Kedrova |e verfasserin |4 aut | |
| 700 | 0 | |a Andrey E. Sanzharov |e verfasserin |4 aut | |
| 700 | 0 | |a Elena V. Shirshova |e verfasserin |4 aut | |
| 700 | 0 | |a Olga I. Balionis |e verfasserin |4 aut | |
| 700 | 0 | |a Vladimir T. Valuev-Elliston |e verfasserin |4 aut | |
| 700 | 0 | |a Natalia F. Zakirova |e verfasserin |4 aut | |
| 700 | 0 | |a Yaroslav N. Glazov |e verfasserin |4 aut | |
| 700 | 0 | |a Irina A. Panukhina |e verfasserin |4 aut | |
| 700 | 0 | |a Nikolay A. Soloviev |e verfasserin |4 aut | |
| 700 | 0 | |a Alexei G. Vinokurov |e verfasserin |4 aut | |
| 700 | 0 | |a Yu. V. Ivanov |e verfasserin |4 aut | |
| 700 | 0 | |a Valentin N. Vasilev |e verfasserin |4 aut | |
| 700 | 0 | |a Tatyana V. Klypa |e verfasserin |4 aut | |
| 700 | 0 | |a Alexander V. Troitsky |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Клиническая практика |d Eco-vector, 2020 |g 11(2020), 2, Seite 38-50 |w (DE-627)DOAJ078636620 |x 26188627 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2020 |g number:2 |g pages:38-50 |
| 856 | 4 | 0 | |u https://doi.org/10.17816/clinpract35168 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/8ff9fe1e117f46e6a130b2e1ed1f0f40 |z kostenfrei |
| 856 | 4 | 0 | |u https://journals.eco-vector.com/clinpractice/article/viewFile/35168/pdf |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2220-3095 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2618-8627 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2020 |e 2 |h 38-50 | ||